Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04520685 · ClinicalTrials.gov registry record · Phase 2
CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr
A Phase 2 study of Autism Spectrum Disorder, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
- 1
- Study location
NCT04520685 is a Phase 2 study of Autism Spectrum Disorder that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 86 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04520685, a Phase 2 study of Autism Spectrum Disorder, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, placebo-controlled study but all study participants will receive the active study medication at some point during the study for at least 12 weeks, and some children with receive CBD for the entire study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Oral cannabidiol 100mg/mL
Study Locations (1)
Colorado
- Children's Hospital Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2021-12-15 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04520685
The ClinicalTrials.gov registry entry for NCT04520685 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (36% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04520685 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT04520685 about?
NCT04520685 is a clinical study titled "CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr". This is a randomized, placebo-controlled study but all study participants will receive the active study medication at some point during the study for at least 12 weeks, and some children with receive CBD for the entire study.
What is the current status of trial NCT04520685?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2021-12-15. Estimated completion is 2024-12-31.
What conditions does trial NCT04520685 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder.
What interventions are being tested in trial NCT04520685?
The interventions under investigation include: Placebo (DRUG), Oral cannabidiol 100mg/mL (DRUG).
Who is sponsoring clinical trial NCT04520685?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04520685 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
RECRUITING · Phase 2
-
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
RECRUITING · Phase 2
-
Optimizing Outcomes for Young Autistic Children
RECRUITING · Phase 2
-
Trial of Zolpidem for Sleep in Children With Autism
RECRUITING · Phase 2
-
Telehealth-Enabled Versus In-Person Parent-Mediated Behavioral Treatment for Challenging Behaviors in Children With ASD
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.